Abcam
Abcam plc, commonly known as Abcam, is a leading life sciences company headquartered in Cambridge, GB. Founded in 1998, Abcam has established itself as a prominent player in the biotechnology industry, specialising in the production and distribution of high-quality antibodies and related products. With a strong focus on research and development, the company serves a global market, with significant operations across Europe, North America, and Asia. Abcam's core offerings include a vast range of antibodies, proteins, and assays, which are renowned for their specificity and reliability. The company’s commitment to innovation and quality has positioned it as a trusted partner for researchers in academia and industry alike. Notable achievements include a robust portfolio of over one million products, making Abcam a go-to resource for scientists seeking advanced tools for their research.
DitchCarbon Score
How does Abcam's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abcam's score of 24 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Abcam's reported carbon emissions
In 2022, Abcam reported total carbon emissions of approximately 102,263,000 kg CO2e, with emissions distributed across various scopes: 1,224,000 kg CO2e from Scope 1, 3,370,000 kg CO2e from Scope 2, and a significant 97,669,000 kg CO2e from Scope 3. This marked an increase from 2021, where total emissions were about 87,856,000 kg CO2e, comprising 1,111,000 kg CO2e from Scope 1, 4,113,000 kg CO2e from Scope 2, and a substantial 82,632,000 kg CO2e from Scope 3. In the UK, Abcam's emissions for 2021 were reported at approximately 1,272,000 kg CO2e, with 494,000 kg CO2e from Scope 1 and 778,000 kg CO2e from Scope 2. The company has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, indicating a potential area for future commitment. Abcam's emissions data reflects its operational footprint and highlights the importance of addressing Scope 3 emissions, which constitute the majority of its carbon impact. The company continues to navigate its climate commitments within the broader context of the life sciences industry, where sustainability is increasingly critical.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 1,554,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 3,198,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 4,752,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abcam is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
